Market Advisors, Inc. Initiates Coverage on Oncolin Therapeutics, Inc.

HOUSTON--(Business Wire)--
Oncolin Therapeutics, Inc., (OTCBB:OCOL) announces that Market
Advisors, Inc. has initiated coverage on the Company with an
intermediate term price target of $1.45.

Market Advisors coverage comes at a time when Oncolin is
developing a new drug for brain cancer, ONC-127, which at present is
in preclinical development. This innovative drug blocks the use
(metabolism) of glucose, the key sugar used to produce energy in tumor
cells. The Company has obtained an exclusive option agreement with the
University of Texas M.D. Anderson Cancer Center which provides the
Company the right to negotiate a license for five technologies
relating to the treatment of various cancers over a nine month period.

Officers of Market Advisors, Inc. have been in business since 1983
and have provided stock market research for their clients since 1985.
Company officials have been frequently quoted in a wide array of
financial publications such as the Wall Street Journal, Investors
Business Daily, and Barron's.

About Oncolin Therapeutics, Inc.

Headquartered in Houston, Texas, Oncolin Therapeutics, Inc. is a
publicly traded biopharmaceutical company that engages in the
discovery, development and commercialization of novel selective
anticancer therapies. Additional information about Oncolin can be
found on the web at www.oncolinthera.com.

Safe Harbor Statement

This press release contains statements that may constitute
forward-looking statements, including the company's ability to
successfully acquire and develop technologies that are and may be
acquired. These statements are based on current expectations and
assumptions and involve a number of uncertainties and risks that could
cause actual results to differ materially from those currently
expected. The information and opinions in this analyst report were
prepared by Market Advisors, Inc. (located in Nebraska) who does
receive fees for services including preparation of this report. For
this report, officers of Market Advisors, Inc received $3,000 from the
Company. For additional information about Oncolin's future business
and financial results, refer to Oncolin's Quarterly Report on Form
10-QSB for the quarter ended December 31, 2007 and Annual Report on
Form 10-KSB for the year ended March 31, 2007. Oncolin Therapeutics
undertakes no obligation to update any forward-looking statement that
may be made from time to time by or on behalf of the company, whether
as a result of new information, future events or otherwise.

Oncolin Therapeutics, Inc., Houston
J. Leonard Ivins, 713-621-5208
Investors@oncolinthera.com

Copyright Business Wire 2008